VAXELIS is the CDC’s only preferred Hib combination vaccine for American Indian and Alaska Native infants.1

The CDC has added VAXELIS to its preferential recommendation for American Indian and Alaska Native infants based on the Haemophilus influenzae type b (Hib) component.1

As you evaluate the needs of your patients, have you considered the vaccination needs of your American Indian and Alaska Native (AI/AN) infants? Native American Indian and Alaska Native (AI/AN) infants are at greater risk for invasive Haemophilus influenzae type b (Hib) disease, yet they are under-vaccinated.1,2 VAXELIS is the only preferred Hib combination vaccine for these babies.1 Consider the information below as you evaluate VAXELIS for your practice.

Native Communities: Beyond Tribal Areas

  • As of 2023, over 8.8 million AI/AN individuals reside in the US.3,a
  • Per the 2020 Census, those who identify as AI/AN are not confined to tribal areas and are dispersed throughout the US.⁠3,4
    • 87% live outside of reservations or other trust lands
    • 60% live in metropolitan areas
  • In 2023, approximately 43% of those who identified as AI/AN had private health insurance coverage.3

AI/AN Infants and Hib Disease⁠

  • AI/AN children are particularly vulnerable to invasive Haemophilus influenzae type b (Hib) disease, with a notably higher incidence occurring at younger ages compared to other populations.⁠5,6
  • Among children born in 2020 and 2021, data from the US Child National Immunization Survey: 2021-2023 (n=28,668 children) indicated that AI/AN children were less likely to complete the full Hib vaccination series by 24 months of age compared to their White counterparts, highlighting a gap in preventive care.2
    • White only, non-Hispanic (n=16,656) – 77.9%2
    • AI/AN only, non-Hispanic (n= 316) – 72.2%2

Why Choose VAXELIS

  • VAXELIS includes PRP-OMP (polyribosylribitol phosphate-meningococcal outer membrane protein), which is the Hib component on which the CDC based their preferential recommendation.1

aAI/AN individuals included in this demographic data identify as AI/AN alone or in combination with one or more races.

Order VAXELIS now

Order directly at: VaccineShop.com. For a list of authorized distributors: VaxelisContract.com

Additional topics to explore

Schedule & dosing

Schedule & dosing

Potential efficiencies

Potential efficiencies

Prep and admin comparisons

Prep and admin comparisons

References: 1. Collins JP, Loehr J, Chen WH, Clark M, Pinell-McNamara V, McNamara LA. Use of Haemophilus influenzae Type b–Containing Vaccines Among American Indian and Alaska Native Infants: Updated Recommendations of the Advisory Committee on Immunization Practices ― United States, 2024. MMWR Morb Mortal Wkly Rep 2024;73:799–802. DOI: http://dx.doi.org/10.15585/mmwr.mm7336a4. 2. Hill HA, Yankey D, Elam-Evans LD, et al. Decline in Vaccination Coverage by Age 24 Months and Vaccination Inequities Among Children Born in 2020 and 2021 — National Immunization Survey-Child, United States, 2021–2023. MMWR Morb Mortal Wkly Rep 2024;73:844–853. DOI: http://dx.doi.org/10.15585/mmwr.mm7338a3 3. U.S. Department of Health & Human Services, Office of Minority Health. American Indian/Alaska Native Health. Updated November 8, 2024. Accessed November 21, 2024. https://minorityhealth.hhs.gov/american-indianalaska-native-health 4. U.S. Census Bureau. American Indians and Alaska Natives in the United States Wall Map. 2020. https://www2.census.gov/geo/maps/DC2020/AIANWall2020/2020_AIAN_US.pdf 5. Gilsdorf JR. Hib Vaccines: Their Impact on Haemophilus influenzae Type b Disease. J Infect Dis. 2021 Oct; 224(4):S321-S330. doi:10.1093/infdis/jiaa537 6. Brown NE, Blain AE, Burzlaff K, Harrison LH, Petit S, Schaffner W, et al. Racial Disparities in Invasive Haemophilus influenzae Disease—United States, 2008–2017. Clinical Infectious Diseases. 2021 Nov;73(9):1617–1624. doi:10.1093/cid/ciab449

Indication for VAXELIS

VAXELIS is a vaccine indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b (Hib). VAXELIS is approved for use as a 3-dose series in children 6 weeks through 4 years of age (prior to the 5th birthday).

Important Safety Information

  • Do not administer VAXELIS to anyone with a history of severe allergic reaction to a previous dose of VAXELIS, any ingredient of VAXELIS, or any other diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, inactivated poliovirus vaccine, hepatitis B vaccine, or Hib vaccine.
  • Do not administer VAXELIS to anyone with a history of encephalopathy within 7 days of a pertussis-containing vaccine with no other identifiable cause.
  • Do not administer VAXELIS to anyone with a history of progressive neurologic disorder until a treatment regimen has been established and the condition has stabilized.
  • Carefully consider benefits and risks before administering VAXELIS to persons with a history of: fever ≥40.5°C (≥105°F), hypotonic-hyporesponsive episode (HHE), or persistent, inconsolable crying lasting ≥3 hours within 48 hours after a previous pertussis-containing vaccine; and/or seizures within 3 days after a previous pertussis-containing vaccine.
  • If Guillain-Barré syndrome occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, the risk for Guillain-Barré syndrome may be increased following VAXELIS.
  • Apnea following intramuscular vaccination has been observed in some infants born prematurely. Consider the individual infant’s medical status and potential benefits and possible risks of intramuscular vaccination in deciding when to administer VAXELIS to an infant born prematurely.
  • Vaccination with VAXELIS may not protect all individuals.
  • The solicited adverse reactions 0-5 days following any dose were irritability (≥55%), crying (≥45%), injection site pain (≥44%), somnolence (≥40%), injection site erythema (≥25%), decreased appetite (≥23%), fever ≥38.0°C (≥19%), injection site swelling (≥18%), and vomiting (≥9%).
  • The 3-dose immunization series consists of a 0.5 mL intramuscular injection, administered at 2, 4, and 6 months of age.
  • A 3-dose series of VAXELIS does not constitute a primary immunization series against pertussis; an additional dose of pertussis-containing vaccine is needed to complete the primary series.

Before administering VAXELIS, please read the accompanying Prescribing Information. The Patient Information also is available.

Indication for VAXELIS® (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine)

VAXELIS is a vaccine indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b (Hib). VAXELIS is approved for use as a 3-dose series in children 6 weeks through 4 years of age (prior to the 5th birthday).

VAXELIS is a vaccine indicated for active immunization to prevent diphtheria, tetanus,

VAXELIS is a vaccine indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b (Hib). VAXELIS is approved for use as a 3-dose series in children 6 weeks through 4 years of age (prior to the 5th birthday).

Important Safety Information for VAXELIS® (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine)

  • Do not administer VAXELIS to anyone with a history of severe allergic reaction to a previous dose of VAXELIS, any ingredient of VAXELIS, or any other diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, inactivated poliovirus vaccine, hepatitis B vaccine, or Hib vaccine.
  • Do not administer VAXELIS to anyone with a history of encephalopathy within 7 days of a pertussis-containing vaccine with no other identifiable cause.
  • Do not administer VAXELIS to anyone with a history of progressive neurologic disorder until a treatment regimen has been established and the condition has stabilized.
  • Carefully consider benefits and risks before administering VAXELIS to persons with a history of: fever ≥40.5°C (≥105°F), hypotonic-hyporesponsive episode (HHE), or persistent, inconsolable crying lasting ≥3 hours within 48 hours after a previous pertussis-containing vaccine; and/or seizures within 3 days after a previous pertussis-containing vaccine.
  • If Guillain-Barré syndrome occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, the risk for Guillain-Barré syndrome may be increased following VAXELIS.
  • Apnea following intramuscular vaccination has been observed in some infants born prematurely. Consider the individual infant’s medical status and potential benefits and possible risks of intramuscular vaccination in deciding when to administer VAXELIS to an infant born prematurely.
  • Vaccination with VAXELIS may not protect all individuals.
  • The solicited adverse reactions 0-5 days following any dose were irritability (≥55%), crying (≥45%), injection site pain (≥44%), somnolence (≥40%), injection site erythema (≥25%), decreased appetite (≥23%), fever ≥38.0°C (≥19%), injection site swelling (≥18%), and vomiting (≥9%).
  • The 3-dose immunization series consists of a 0.5 mL intramuscular injection, administered at 2, 4, and 6 months of age.
  • A 3-dose series of VAXELIS does not constitute a primary immunization series against pertussis; an additional dose of pertussis-containing vaccine is needed to complete the primary series.

Before administering VAXELIS, please read the accompanying Prescribing Information. The Patient Information also is available.

  • Do not administer VAXELIS to anyone with a history of severe allergic reaction to a previous dose of VAXELIS, any ingredient of VAXELIS, or any other diphtheria toxoid,
  • Do not administer VAXELIS to anyone with a history of severe allergic reaction to a previous dose of VAXELIS, any ingredient of VAXELIS, or any other diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, inactivated poliovirus vaccine, hepatitis B vaccine, or Hib vaccine.
  • Do not administer VAXELIS to anyone with a history of encephalopathy within 7 days of a pertussis-containing vaccine with no other identifiable cause.
  • Do not administer VAXELIS to anyone with a history of progressive neurologic disorder until a treatment regimen has been established and the condition has stabilized.